LIXT
Lixte Biotechnology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About LIXT
Lixte Biotechnology Holdings, Inc.
A clinical-stage pharmaceutical company that focused on new targets for cancer therapies
680 East Colorado Boulevard, Suite 180, Pasadena, California 91101
--
Lixte Biotechnology Holdings, Inc., was incorporated on May 24, 2005 in the name of a Delaware corporation under the name SRKP 7, Inc. On December 7, 2006, the company changed its name to Lixte Biotechnology Holdings, Inc. The company is a drug discovery company. Use biomarkers to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. The company's product line focuses primarily on protein phosphatase inhibitors, which can be used alone or in combination with cytotoxic agents and X-ray and immune checkpoint blockers, covering two broad classes of compounds in all stages of preclinical and clinical development.
Company Financials
EPS
LIXT has released its 2023 Q3 earnings. EPS was reported at -0.49, versus the expected 0.00, missing expectations. The chart below visualizes how LIXT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
